Advertisement
UK markets close in 1 hour 27 minutes

  • FTSE 100

    7,853.38
    -23.67 (-0.30%)
     

  • FTSE 250

    19,337.20
    -113.47 (-0.58%)
     

  • AIM

    743.88
    -1.41 (-0.19%)
     

  • GBP/EUR

    1.1681
    -0.0002 (-0.02%)
     

  • GBP/USD

    1.2459
    +0.0020 (+0.16%)
     

  • Bitcoin GBP

    52,128.27
    +1,722.09 (+3.42%)
     

  • CMC Crypto 200

    1,384.34
    +71.71 (+5.78%)
     

  • S&P 500

    5,011.97
    +0.85 (+0.02%)
     

  • DOW

    37,947.47
    +172.09 (+0.46%)
     

  • CRUDE OIL

    82.64
    -0.09 (-0.11%)
     

  • GOLD FUTURES

    2,397.00
    -1.00 (-0.04%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,761.68
    -75.72 (-0.42%)
     

  • CAC 40

    8,025.85
    +2.59 (+0.03%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

BUZZ-Shire: Gattex, Natpara & Vyvanse possible blockbusters-UBS

Reuters - UK Focus

** Shire (Xetra: S7E.DE - news) 3rd-top FTSE 100 riser as UBS (NYSEArca: FBGX - news) hikes TP to 6,600p vs 5,400p, saying co likely did not overpay for NPS Pharmaceuticals

** The $5.2 bln NPS acquisition gave Shire 2 key new drugs - Gattex & Natpara; UBS says both should become blockbusters

** UBS also sees scope for Vyvanse - Shire's big-selling hyperactivity drug which FDA recently approved for binge eating - to become a blockbuster

** Blog Betaville said co has sights on combining with US rare genetic diseases specialist BioMarin Pharmaceutical (NasdaqGS: BMRN - news) . Link: http://bit.ly/1ICuVHC

ADVERTISEMENT

** Called down 0.5-1 pct in pre-market by brokers, say deal unlikely

** Shire, which was set to be bought by AbbVie (LSE: 0QCV.L - news) last year for 5,248p a share, up 1.4 pct at 5,385p (US group pulled plug on the $55 bln deal after changes to US tax rules) (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)